NAPA, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced the debut of Pyratine-6(TM) at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio, Texas.
Pyratine-6(TM), Senetek's exclusive second generation cytokinin, has been clinically proven to be effective in correcting visible signs of skin aging and significantly reducing erythema as early as two weeks from onset of use.
The Annual Meeting of the American Academy of Dermatology runs from February 1 - 5, 2008. Approximately 7,000 medical personnel are registered to attend.
Commenting on the debut, Mr. Frank Massino, Senetek's Chairman and Chief Executive Officer stated, "We are delighted to see this compelling therapeutic come to the market and are very pleased by the reception Pyratine-6(TM) has received from dermatologists at this important conference. Pyratine-6(TM) has been successfully clinically tested and has shown attributes more beneficial to treatment than any predecessor compound."
About Senetek PLC
Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.
For more information, visit the company's website at http://www.senetekplc.com.
This news release contains
|SOURCE Senetek PLC|
Copyright©2008 PR Newswire.
All rights reserved